11:54 AM EST - Valeant Pharmaceuticals International, Inc. : announced second-quarter financial results for 2013. Valeant's total revenues were $1.1 billion, up 34% compared to the second quarter of 2012, and product revenues were $1.06 billion, up 43% versus the year-ago quarter. The Company reported net income of $11 million for the second quarter of 2013, or $0.03 per diluted share. On a Cash EPS basis, adjusted income was $421 million, or $1.34 per diluted share. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $0.94 at $100.52.
